​

NewAmsterdam Pharma (NAMS) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

NewAmsterdam Pharma Revenue Highlights

Latest Revenue (Y)

$45.56M

Latest Revenue (Q)

$2.13M

Main Segment (Y)

License Revenue

NewAmsterdam Pharma Revenue by Period

NewAmsterdam Pharma Revenue by Year

DateRevenueChange
2024-12-31$45.56M257.00%
2023-12-31$12.76M-86.69%
2022-12-31$95.91M100.00%
2021-12-31-100.00%
2020-12-31--

NewAmsterdam Pharma generated $45.56M in revenue during NA 2024, up 257.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

NewAmsterdam Pharma Revenue by Quarter

DateRevenueChange
2024-06-30$2.13M63.86%
2024-03-31$1.30M-18.58%
2023-12-31$1.59M-15.06%
2023-09-30$1.88M19.31%
2023-06-30$1.57M-80.22%
2023-03-31$7.96M515.29%
2022-12-31$1.29M-76.98%
2022-09-30$5.62M-87.98%
2022-06-30$46.75M-
2022-03-31$46.75M100.00%
2021-12-31-100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31-100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31--

NewAmsterdam Pharma generated $2.13M in revenue during Q2 2024, up 63.86% compared to the previous quarter, and up 26.74% compared to the same period a year ago.

NewAmsterdam Pharma Revenue Breakdown

NewAmsterdam Pharma Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 22
License Revenue$97.50M

NewAmsterdam Pharma's latest annual revenue breakdown by segment (product or service), as of Dec 22: License Revenue (100.00%).

Quarterly Revenue by Product

Product/ServiceJun 23
License Revenue$4.56M

NewAmsterdam Pharma's latest quarterly revenue breakdown by segment (product or service), as of Jun 23: License Revenue (100.00%).

NewAmsterdam Pharma Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
GLUEMonte Rosa Therapeutics$75.62M$4.70M
NAMSNewAmsterdam Pharma$45.56M$2.13M
MRUSMerus$36.13M$11.77M
IVAInventiva$17.48M$2.73M
JANXJanux Therapeutics$10.59M$8.90M
MOLNMolecular Partners$7.04M$2.74M
PRTCPureTech Health$3.33M$178.57K
CRNXCrinetics Pharmaceuticals$1.04M-
ANEBAnebulo Pharmaceuticals--
RZLTRezolute--
CGEMCullinan Oncology--
CMPXCompass Therapeutics--
REPLReplimune Group--
MLYSMineralys Therapeutics--
PEPGPepGen--

NAMS Revenue FAQ

What is NewAmsterdam Pharma’s yearly revenue?

NewAmsterdam Pharma's yearly revenue for 2024 was $45.56M, representing an increase of 257.00% compared to 2023. The company's yearly revenue for 2023 was $12.76M, representing a decrease of -86.69% compared to 2022. NAMS's yearly revenue for 2022 was $95.91M, representing an increase of 100.00% compared to 2021.

What is NewAmsterdam Pharma’s quarterly revenue?

NewAmsterdam Pharma's quarterly revenue for Q2 2024 was $2.13M, a 63.86% increase from the previous quarter (Q1 2024), and a 35.21% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $1.3M, a -18.58% decrease from the previous quarter (Q4 2023), and a -83.68% decrease year-over-year (Q1 2023). NAMS's quarterly revenue for Q4 2023 was $1.59M, a -15.06% decrease from the previous quarter (Q3 2023), and a 23.33% increase year-over-year (Q4 2022).

What is NewAmsterdam Pharma’s revenue growth rate?

NewAmsterdam Pharma's revenue growth rate for the last 3 years (2022-2024) was -52.49%, and for the last 5 years (2020-2024) was 0%.

What are NewAmsterdam Pharma’s revenue streams?

NewAmsterdam Pharma's revenue streams in c 22 are License Revenue

What is NewAmsterdam Pharma’s main source of revenue?

For the fiscal year ending Dec 22, the largest source of revenue of NewAmsterdam Pharma was License Revenue. This segment made a revenue of $97.5M, representing 100.00% of the company's total revenue.